VAXCYTE, INC. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
VAXCYTE, INC. (PCVX) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount of $139.66 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-02-24
- VAXCYTE, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2025 was $139.66M, a 28.59% increase from fiscal 2024.
- VAXCYTE, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2024 was $108.61M, a 23.78% increase from fiscal 2023.
- VAXCYTE, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, amount for fiscal 2023 was $87.74M.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount 12 month |
|---|---|
| 2025-12-31 | $139.66M 10-K · filed 2026-02-24 |
| 2024-12-31 | $108.61M 10-K · filed 2026-02-24 |
| 2023-12-31 | $87.74M 10-K · filed 2026-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |